focus -WSS

focus

author：hotspot 2025-08-31 02:01:37 - browse：4

From left: Daphne Koller, CEO of Insitro, Vijay Pande of Andreessen Horowitz and scientist Derek Lowe speaking at STAT's Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing.

To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens. All you need to get to a cure — as they say in infomercials — is act now!

“I am very worried about the hype,” said Daphne Koller, chief executive of the machine learning drug discovery company Insitro, said during STAT’s Breakthrough West Summit in San Francisco last week. “People think (the breakthrough) is going to happen tomorrow.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Roivant's CEO is a star, but biotech's black hole persists

WSS

FDA clears Verve to begin U.S. study of gene

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Questions loom on AstraZeneca cancer drug as safety concerns ebb

STAT Summit: How researchers deal with rejection

J&J lung cancer data amount to new salvo against AstraZeneca

US intelligence assessment says Iran not currently developing nuclear weapons

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Medicare details structure of new drug price negotiation program

With fresh data, a dynamic duo powers Eli Lilly to new heights

Trump demands the U.S. pay no more for drugs than other countries … again

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Anesthesiologist group: stop taking Ozempic before surgery

The problems with dementia villages

entertainment

Why Titanic fascinates society, still drawing tours to the wreckage

CZI to create biohub to build anti

CZI to create biohub to build anti

How AI can help patients find reliable information about doctors

How corporate America is slashing DEI workers amid backlash to diversity programs

Why Titanic fascinates society, still drawing tours to the wreckage

hotspot

hotspot

knowledge

knowledge